Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...The African Union intervened last week, announcing that it had agreed to purchase 270m doses for its 54 member countries from Pfizer, AstraZeneca via the Serum Institute and Johnson & Johnson....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...But the lack of scrutiny on the product continues to raise red flags, our deputy editor Patrick Jenkins argues....
...Doubtful drugmakers Erik Nordkamp, the managing director of Pfizer UK, warns that the UK pharmaceuticals industry, which employs more than 140,000 people, urgently needs reform....
...A decade ago, Jeffrey Kindler, then chief executive of US drugs giant Pfizer, was plotting an audacious $68bn acquisition of rival Wyeth....
...patrick.jenkins@ft.com...
...Collectively 30 companies, which include General Motors, Qualcomm and Pfizer, own nearly $900bn in US debt and equities. But the sheer scale is creating risk, say experts....
...That would help fund an acquisition of Pfizer or Merck’s consumer health businesses, currently under review by those groups....
.... …………………………………………………………………………………………………………… Ben Hall, world news editor, picks: • Isis Inc: how oil fuels jihadi terrorists by Erika Solomon, Guy Chazan and Sam Jones• Why China’s ‘migrant miracle’ is...
...And so it has, for Mr Jenkins....
...And lo, a day of judgment came upon “Saint” Antony Jenkins of the house of Barclays. He was cast among ravening lions – the shareholders – at a place of tribulation called the Royal Festival Hall....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Mr Jenkins is dismantling the investment bank Bob Diamond built and neutralising the toxic issue of bonuses along the way....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...In case you still can’t believe it — we present page 180 of the prospectus for Madrid Activos Corporativos V, FTA: Full document (in Spanish) in the usual place....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...But the timing could have been better notes Gary Jenkins of Evolution Securities (emphasis ours): Moody’s has placed the Aa1 rating of Spain on review for downgrade....
...Why does a Goldman Sachs rack up a return on equity of 22 per cent, when a BP makes 17 per cent, or a Pfizer makes 12 per cent – especially when so many of the now booming banks were at least partly responsible...
...He no longer owns Idol and five years ago sold his company, 19 Entertainment, to media group CKX Inc....
...General Electric slashed payments by nearly $9bn, Pfizer cut $4.3bn. 2009 has turned out to be record year in terms of dividend cuts in the US....
...“Is this a V recovery or a W?” Mr Geoghegan asked in an interview with the FT. “[I think] it’s the latter....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
International Edition